Glaxo Group Limited

Glaxo Wellcome Spa

Chronos Therapeutics Limited

Barbara Bertani

Fabrizio Micheli

Alessandra Pasquarello

Romano Di Fabio

Silvia Terreni

Luca Tarsi

Simon Edward Ward

Colin Philip Leslie

Susanna Cremonesi

Giovanna Tedesco

Gabriella Gentile

Markus Bergauer

Anna Checchia

Jessica Tibasco

Alessandro Falchi

Domenica Antonia Pizzi

Matteo Biagetti

Giancarlo Merlo

Marilisa Rinaldi

Luigi Piero Stasi

Steven Mark Bromidge

Antonio Kuok Keong Vong

Karl Richard Gibson

Paolo Dambruoso

Giorgio Bonanomi

Teresa Semeraro

Stefano Fontana

Anna Maria Capelli

Alfonso Pozzan

Francesca Cardullo

Luca Raveglia

Timothy Jon Luker

Riccardo Zanaletti

Simone Giacobbe

Paola Marzorati

Catia Seri

There is provided a compound of formula (I), wherein Lto L', Rto R, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists

The present invention relates to certain azabicyclo compounds of formula (I)': wherein the various groups are defined herein and that are modulators of dopamine Dreceptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, or premature ejaculation.

[object Object]

The present invention relates to novel compounds of formula (I) or a salt thereof: wherein

The present invention relates to novel compounds of formula (I) or a salt thereof: wherein Ris a 5-membered heteroaryl group, optionally fused with a 6-membered hetero or carbocycle; such 5 or 11-membered system, may be optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, Calkyl, haloCalkyl, Calkoxy, Calkanoyl, haloCalkoxy and SF; and n is 1 or 2; their use in therapy, as modulators of dopamine Dreceptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, or premature ejaculation.

Azabicyclo [3. 1. O] hexyl derivatives as modulators of dopamine D3 receptors

The present invention relates to certain azabicyclic compounds of formula (I)': wherein the several groups are defined herein and are modulators of dopamine Dreceptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, or premature ejaculation.

Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine D3 receptors

The present invention relates to compounds of formula (I) or salts thereof wherein A, X, R, Rand n are defined herein, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine Dreceptors, e.g., to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, premature ejaculation or to enhance cognition.

Spirocompounds useful as modulators for dopamine D3 receptors

Disclosed are methods for the preparation of compounds of formula (I): wherein R, m, X, R, n, W, p, Y, Z, R, R, Rand q have the meanings as defined in the description.

Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors

The present invention relates to novel compounds of formula (I)' or a salt thereof: wherein and the other groups are define in herein.

Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione

Disclosed are methods for use of compounds of formula (I) in combination with other active substances in the treatment of CNS disorders such as depression or anxiety. wherein R, m, X, R, n, W, p, Y, Z, R, R, Rand q have the meanings as defined in the description.

Tetrahydroquinolines as NMDA antagonists

Growing community of inventors

Verona, Italy

Barbara Bertani